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SUMMARY
Here, we report that MYC rescues early human
cells undergoing reprogramming from a proliferation
pause induced by OCT3/4, SOX2, and KLF4 (OSK).
We identified ESRG as a marker of early reprogram-
ming cells that is expressed as early as day 3 after
OSK induction. On day 4, ESRGpositive (+) cells con-
verted to a TRA-1-60 (+) intermediate state. These
early ESRG (+) or TRA-1-60 (+) cells showed a prolif-
eration pause due to increased p16INK4A and p21
and decreased endogenous MYC caused by OSK.
Exogenous MYC did not enhance the appearance
of initial reprogramming cells but instead reactivated
their proliferation and improved reprogramming effi-
ciency. MYC increased expression of LIN41, which
potently suppressed p21 post-transcriptionally.
MYC suppressed p16 INK4A. These changes inacti-
vated retinoblastoma protein (RB) and reactivated
proliferation. The RB-regulated proliferation pause
does not occur in immortalized fibroblasts, leading
to high reprogramming efficiency even without exog-
enous MYC.
INTRODUCTION
Enforced expression of specific transcription factors (OCT3/4,
SOX2, KLF4, and MYC, abbreviated as OSKM) reprograms
somatic cells toward pluripotency (Takahashi et al., 2007; Taka-
hashi and Yamanaka, 2006). These factors induce dynamic
changes in gene expression, such as the suppression of somatic
cell genes and activation of pluripotency-associated genes (Bu-
ganim et al., 2013). Initially, all four factors were thought to be
essential for reprogramming. However, exogenous MYC is
dispensable, even though it greatly enhances the efficiency of re-
programming by OCT3/4, SOX2, and KLF4 (OSK) (Nakagawa
et al., 2008; Wernig et al., 2008). Many factors promote OSK-
mediate reprogramming, but MYC remains one of the strongest
activators of induced pluripotent stem cell (iPSC) generation.
MYC was one of the first proto-oncogenes identified in hu-
mans more than 30 years ago (Hayward et al., 1981; Vennstrom
et al., 1982). Overexpression of MYC is a hallmark associated
with up to 70% of all human cancers (Ciriello et al., 2013;
Dang, 2012; Gabay et al., 2014). It belongs to a basic helix-
loop-helix-leucine-zipper (bHLH-Zip) family of transcription
factors and requires the partner protein MAX to bind canonical
E-box elements (CACGTG) or other non-canonical variants
(CANNTG) (Blackwell et al., 1990; Blackwood and Eisenman,
1991; Lin et al., 2012). MYC primarily functions as a transcription
activator through interaction with other activators, such as his-
tone acetyltransferases and Mediator (Vervoorts et al., 2003).
However, MYC can also function as a transcriptional suppressor
by interacting with other partners, such as MIZ1 and polycomb
repressive complex (PRC) 2 (Haupt et al., 1991; Peukert et al.,
1997; van Lohuizen et al., 1991). In addition, MYC may function
as a universal amplifier of expressed genes (Lin et al., 2012; Wolf
et al., 2015).
MYC is involved in various biological processes. It stimulates
the cell cycle by promoting DNA synthesis (Dominguez-Sola
and Gautier, 2014). It alters metabolism from oxidative phos-
phorylation to glycolysis, the latter of which is active in pluripo-
tent stem cells and cancer cells (Cliff et al., 2017; Dang, 2013,
2015; Folmes et al., 2013). MYC also activates non-coding
RNAs, including microRNAs (miRNAs), such as miR17–miR92
expression in mouse embryonic stem cells (ESCs) (Lin et al.,
2009; Smith et al., 2010).MYC regulates, and inmany cases sup-
presses, developmental genes such as GATA6 and HOX genes
(Chappell and Dalton, 2013). In addition, MYC affects signaling
pathways. For example, MYC suppresses the ERK/mitogen-
activated protein kinase (MAPK) pathway through DUSP2/7,
whereas it activates the Wnt pathway through PRC2 (Chappell
et al., 2013; Fagnocchi et al., 2016). Moreover, MYC can induce
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 d0 d7 d0 < d7 d0 > d7
HDF OSKM 1526 982
HAdMSC OSKM 1703 1512
HA OSKM 1017 1032
HBEC OSKM 1051 1146
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Figure 1. Identifying the Early Marker of Reprogramming
(A) Extraction of commonly changed genes and narrowing of the candidates for reprogrammingmarker.We usedmicroarrays to compare global gene expression
of somatic cells (HDFs, HAdMSCs, HAs, HBECs, and HPrECs) on day 0 (d0) and their TRA-1-60 (+) progenies on day 7 (d7) post-transduction of OSKM. n = 3. By
comparing differentially expressed genes between parental cells and TRA-1-60 (+) cells among five cell types, we obtained the indicated common genes. These
commonly changed genes were evaluated by single-cell RNA-seq to narrow down the candidates. Blue boxes show the criteria of analyses. See also Tables S1
and S2.
(B) Expression of ESRG during reprogramming. Shown are the results of expressing ESRG in parental HDFs (d0), OSKM-expressing cells on day 3 (d3), TRA-1-60
(+) cells at the indicated time points (days 7–28), and iPSCs analyzed by single-cell RNA-seq. Twenty-four single cells were analyzed for each time point. Red dots
indicate median values. Gray hourglass shapes represent the distribution of the reads per kilobase of transcript, per million mapped reads (RPKM) + 1 value. See
also Figure S1.
(legend continued on next page)
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global epigenomic changes that affect binding of other transcrip-
tion factors and nuclear architecture (Kieffer-Kwon et al., 2017;
Kress et al., 2015).
MYC facilitates early stages of reprogramming, but the molec-
ular mechanism remains controversial (Polo et al., 2012; Soufi
et al., 2012; Sridharan et al., 2009). It may enhance early
steps of reprogramming by repressing fibroblast-specific gene
expression and upregulating the metabolic program of the em-
bryonic state (Sridharan et al., 2009). This paper also showed
that exogenous MYC is required during the initial 5 days after
OSK induction to promote iPSC generation. Alternatively, MYC
may facilitate binding of OSK factors to their target genes in
the first 48 hr of reprogramming (Soufi et al., 2012). Another
study showed that MYC, together with KLF4, elicits the first
wave of changes during reprogramming, including induction of
proliferation, metabolic changes, and loss of genetic program
of fibroblasts (Polo et al., 2012). Thus, how MYC promotes early
stages of reprogramming remains unclear (Knoepfler, 2008).
In the current study, we used three unprecedented opportu-
nities to clarify the role of MYC during reprogramming. First,
we identified a specific marker of reprogramming that is acti-
vated as early as 3 days after OSKM introduction. This allowed
us to examine the role of MYC in the early stages during human
iPSC generation. Because only a small fraction of cells that
receive OSK or OSKM can start reprogramming, data would
be misleading without purification using a specific marker. Sec-
ond, we generated teratoma-derived fibroblasts (TdFs) that
reprogram as efficiently using OSK alone as with OSKM. Exoge-
nous MYC did not enhance iPSC generation in this line. To our
knowledge, this is the only identified cell line for which reprog-
ramming is not enhanced by exogenous MYC. Therefore, TdFs
provide a unique tool to help determine the role of MYC. Third,
as we previously described, the heterochronic developmental
factor LIN41/TRIM71, like MYC, enhances reprogramming
when added to OSK (Worringer et al., 2014). Here, we provide
a clear molecular mechanism by which LIN41 enhances reprog-
ramming and demonstrate that this function is closely related to
MYC; it is a critical downstream effector for MYC-enhancement
of reprogramming. Collectively, our data show that MYC pro-
motes human iPSC generation primarily by facilitating the
escape of an OSK-induced proliferation blockade in early re-
programming cells. It does this by repressing retinoblastoma
protein (RB) rather than enhancing OSK binding, suppressing
fibroblast-specific genes, or inducing metabolic changes.
RESULTS
ESRG Is an Early Marker of Human Cellular
Reprogramming
To understand what happens in the initial phase of reprogram-
ming, we tried to identify markers that detect reprogramming
cells before TRA-1-60. We analyzed the global gene expression
of five human somatic cell types—i.e., human dermal fibroblasts
(HDFs, mesoderm), human adipose-derived mesenchymal stem
cells (HAdMSCs, mesoderm), human astrocytes (HAs, ecto-
derm), human bronchial epithelial cells (HBECs, endoderm),
and human prostate epithelial cells (HPrECs, endoderm)—and
their TRA-1-60 (+) reprogramming progenies on day 7 after intro-
duction of OSKM (fold change [FC] > 5.0, false discovery rate
[FDR] < 0.05) using gene expression arrays (Figure 1A). We
identified 194 upregulated genes (Table S1) and 74 down-
regulated genes (Table S2) that were common in all five somatic
cells. Known early reprogramming markers (e.g., L1TD1, SALL4,
and NANOG) and other pluripotency-associated genes (e.g.,
TGDF1, DNMT3L, and ESRG) were among the upregulated
genes (Buganim et al., 2012; O’Malley et al., 2013; Takahashi
et al., 2014).
We expected some of the 194 commonly upregulated genes
to function as early markers of reprogramming. We rationalized
that good markers should fulfill the following criteria: (1) unde-
tectable expression in somatic cells, (2) heterogeneous expres-
sion in cells on day 3, and (3) expression in all TRA-1-60 (+) cells
on day 7 (Figure 1A). We used single-cell RNA sequencing
(RNA-seq) to examine parental HDFs, OSKM-expressing cells
on day 3, TRA-1-60 (+) cells on days 7–28, and iPSCs. This anal-
ysis revealed that only one gene, ESRG encoding a human
endogenous retrovirus type H (HERV-H)-driven long non-coding
RNA (lncRNA), fulfilled all three criteria (Figures 1A and 1B)
(Li et al., 2013). We then examined the expression of ESRG dur-
ing iPSC generation from the five types of somatic cells and
confirmed similar expression patterns (Figure 1C). These data
show that ESRG functions as an early marker of reprogramming
toward human iPSCs regardless of starting somatic cell types.
To better monitor ESRG (+) cells, we generated an iPSC line
carrying an ESRG-Clover allele by CRISPR/Cas9-mediated ho-
mologous recombination (Figures S1A–S1E). The resulting re-
porter clone revealed that undifferentiated iPSCs specifically
and uniformly expressed Clover fluorescent proteins driven by
the endogenous ESRG promoter (Figures S1F–S1H). We trans-
duced OSK or OSKM into fibroblasts derived from ESRG-Clover
iPSCs. Before transduction, fibroblasts expressed neither ESRG
nor TRA-1-60 (Figures 1D and S1F–S1H). On day 3, we detected
2.39% ± 0.56% and 2.13% ± 0.54% of ESRG-Clover (+) cells
after transduction of OSK and OSKM, respectively (Figure 1D).
On day 3, we did not detect TRA-1-60 (+) cells, suggesting that
ESRG is activated earlier than TRA-1-60 during reprogramming.
On day 4, a small number (0.96% ± 0.29% by OSK and 0.85% ±
0.22% by OSKM) of ESRG (+)/TRA-1-60 (+) cells emerged (Fig-
ure 1D). The proportion of ESRG (+) cells on day 4 did not signif-
icantly increase from that on day 3 (2.39% versus 3.01% by OSK
and 2.49% versus 2.13% by OSKM) (Figure 1D). In addition,
we used cell sorting to purify ESRG (+) cells on day 3. After
(C) Expression of ESRGduring reprogramming. Shown is the expression of ESRG in parental cells (d0), OSKM-expressing cells on day 3 (d3), TRA-1-60 (+) cells at
the indicated time points (days 7–28) derived from HDFs, and HAdMSCs, HAs, HBECs, and HPrECs analyzed by microarray. n = 3.
(D) TRA-1-60 (+) cells emerged only fromESRG (+) cells. Shown are representative histograms of ESRG-Clover (x axis) and TRA-1-60 (y axis) expression in ESRG-
Clover fibroblasts (day 0) and those on days 3, 5, and 7 post-transduction by OSK or OSKM. n = 3. See also Figure S1.
(E) ESRG (+) cells are origins of iPSCs. We introduced OSKM into ESRG-Clover fibroblasts by retroviral transduction and purified ESRG (+) and ESRG () cells by
cell sorting. Sortedcells (100,000)wereplatedontoMMC-treatedSNL feeder layers. A terminal stainwasperformedwith red alkaline phosphataseonday 24. n=3.
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Figure 2. Cell-Cycle Progression Is Dispensable for Initiating Reprogramming
(A) Gene ontology analyses of genes varied according to ESRG. Top 200 genes reverse correlated to ESRG were classified by the gene ontology analysis. The
p values of the top 10 enriched terms are shown. See also Table S3.
(B) Gene set enrichment analysis showing enrichment of cell-cycle-related genes in the set of genes that show reverse correlation with ESRG expression. x axis
shows genes ranked by the Pearson correlation coefficient for ESRG expression. Left, positively correlated genes; right, negatively correlated genes. See also
Table S3.
(C) Proliferation of ESRG (+) cells. Shown is a representative histogram of the BrdU incorporation of OSKM-transduced ESRG-Clover fibroblasts on day 3. n = 3.
(D) Proliferation of newly converted TRA-1-60 (+) cells fromHDFs. Shown are the percentages of the BrdU incorporation of parental HDFs on day 0 (d0), TRA-1-60
(+) or TRA-1-60 () cells on day 4 (d4) or day 7 (d7). *p < 0.05 by unpaired t test (n = 3).
(E) Proliferation of newly converted TRA-1-60 (+) cells from other cell types. Shown are the percentages of TRA-1-60 (+)/BrdU () (black), TRA-1-60 (+)/BrdU (+)
(red), or TRA-1-60 ()/BrdU (+) cells on day 4 (d4) or day 7 (d7). n = 3.
(F) MYC enhances the proliferation of TRA-1-60 (+) cells. Shown are the percentages of BrdU (+) incorporation in ESRG (+) cells on day 3 (d3) and TRA-1-60 (+)
cells on day 4 (d4) or day 7 (d7) induced by OSK or OSKM. *p < 0.05 by unpaired t test (n = 3).
(G) MYC does not enhance the continuity of TRA-1-60 conversion. Shown are representative immunocytochemistry images of the cells on day 7 derived from
sorted TRA-1-60 (+) or TRA-1-60 () cells in the ESRG (+) population on day 4 post-transduction of OSKM stained with TRA-1-60 (white) and OCT3/4 (red)
antibodies. Nuclei were visualized by Hoechst 33342 staining. Bars indicate 100 mm.
(H) TRA-1-60 () cells on day 4 did not convert to a TRA-1-60 (+) fate. Shown are quantitative results of ESRG (+)/TRA-1-60 (+) cells (red) and ESRG (+)/TRA-
1-60 () cells (green) in the cells shown in (G).
(I) Percentages of ESRG (+) cells from MMC-treated (+) or non-treated () ESRG-Clover fibroblasts on day 3 post-transduction of OSKM. n = 3. See also
Figure S2.
(legend continued on next page)
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re-plating, ESRG (+) cells produced many iPSC colonies,
whereas ESRG () cells resulted in few (Figure 1E). These data
demonstrate that TRA-1-60 (+) intermediate reprogramming
cells and iPSCs emerged only from ESRG (+) cells.
Seven days after OSKM induction, the proportion of ESRG
(+)/TRA-1-60 (+) cells and ESRG (+)/TRA-1-60 () cells rose to
3.64% ± 0.56% and 3.77% ± 0.73%, respectively (Figure 1D).
Thus, the ESRG population on day 7 increased 3-fold from that
of day 4. ESRG ()/TRA-1-60 (+) cells were practically zero by
day 7 (Figure 1D), and OSK induced ESRG (+) cells on day 3
and TRA-1-60 (+) cells on day 4 comparable to OSKM (Fig-
ure 1D). However, without exogenous MYC, the proportion of
ESRG (+)/TRA-1-60 (+) cells and ESRG (+)/TRA-1-60 () cells re-
mained low on day 7 (1.23% ± 0.58% and 2.44% ± 0.52%,
respectively). These data suggest that MYC does not facilitate
initial emergence of ESRG and TRA-1-60 (+) cells but rather
promotes expansion of early reprogramming cells between
day 4 and day 7.
Early Reprogramming Cells Do Not Proliferate
To understand how MYC promotes expansion of early reprog-
ramming cells, we examined gene expression at a single-cell
level 3 days after transduction of OSKM into HDFs. By gene
ontology (GO) analysis, genes with expression levels that
showed reverse correlation with ESRG expression were
significantly enriched with cell-cycle-related terms (Figure 2A;
Table S3). Gene set enrichment analysis (GSEA) indicated that
the expression levels of 612 of 1,076 cell-cycle-related genes
showed reverse correlation to ESRG expression (p = 1.95e10
by Fisher’s exact test) (Figure 2B; Table S3). Based on these re-
sults, we next examined the proliferation profile of early reprog-
ramming cells using bromodeoxyuridine (BrdU) incorporation.
Three days after OSKM induction, BrdU (+) cells were readily
detected in ESRG () cells, but not in ESRG (+) cells (Figure 2C).
This was also the case with TRA-1-60 (+) cells and TRA-1-60 ()
cells on day 4 (Figure 2D). On day 7, BrdU (+) cells significantly
increased in TRA-1-60 (+) cells and decreased in TRA-1-60 ()
cells (Figure 2D). Comparable results were observed in TRA-
1-60 (+) cells on days 4 and 7 after OSKM induction into other
types of somatic cells, including HAdMSCs, HAs, HBECs, and
HPrECs (Figure 2E). These data demonstrated that ESRG (+)
cells do not proliferate when they emerge at day 3 and convert
to TRA-1-60 (+) cells at day 4 after OSKM induction, regardless
of the origin of the somatic cells. By day 7 after OSKM transduc-
tion, however, early reprogramming cells initiate proliferation.
MYC Promotes Proliferation in Reprogramming Cells
We then determined whether proliferation in early reprogram-
ming cells depends on exogenous MYC. We induced OSK or
OSKM and examined the proportion of TRA-1-60 (+) cells on
days 4 and 7. The proportions of new TRA-1-60 (+) cells
induced by OSK or OSKM on day 4 were comparable (Fig-
ure 1D). In contrast, on day 7, we observed increases in the pro-
portion of TRA-1-60 (+) cells with OSKM, but not with OSK (Fig-
ure 1D). This tendency correlated well with BrdU incorporation
into TRA-1-60 (+) cells (Figure 2F). ESRG (+) cells and TRA-1-
60 (+) cells did not incorporate BrdU, except for TRA-1-60 (+)
cells on day 7 after OSKM induction, indicating that MYC
contributed to the re-establishment of proliferation. To confirm
whether MYC promotes proliferation of TRA-1-60 (+) cells rather
than conversion to a TRA-1-60 (+) fate, we separated ESRG (+)/
TRA-1-60 (+) or ESRG (+)/TRA-1-60 () cells on day 4 of reprog-
ramming and analyzed the existence of TRA-1-60 (+) cells on
day 7. Day 4 ESRG (+)/TRA-1-60 () cells produced few TRA-
1-60 (+) cells by day 7 (Figures 2G and 2H), suggesting that
MYC did not promote de novo conversion to a TRA-1-60 (+)
state.
Initiation of ESRG (+) and TRA-1-60 (+) Fate Depends on
Neither Proliferation nor MYC
The finding that early reprogramming cells stop proliferating
prompted us to examine whether proliferation is required for
emergence of ESRG (+) and TRA-1-60 (+) cells. To this end, we
treated ESRG-Clover fibroblasts and HDFs with mitomycin C
(MMC) to arrest their proliferation 1day afterOSKorOSKMtrans-
duction. Counting of treated cells over 7 days showed that MMC
treatment resulted in negligible proliferation, without detectable
BrdU labeling (Figures S2A and S2B). However, ESRG (+) cells
were readily detected even from MMC-treated fibroblasts on
day 3 post-transduction of OSK or OSKM (Figure 2I). The propor-
tion of ESRG (+) cells in MMC-treated cells was comparable to
that of untreated fibroblasts (Figure 2I). This was also the case
with the proportion of TRA-1-60 (+) cells on day 4 (Figure 2J).
On day 7, the proportion of TRA-1-60 (+) cells did not increase
from day 4 in MMC-treated cells, whereas it increased signifi-
cantly in OSKM-transduced, MMC-untreated cells (Figure 2J).
Comparable results were observed with aphidicolin, a reversible
inhibitor of eukaryotic nuclear DNA replication and cell-cycle
progression (Figures S2C and S2D).
Next, we examined whether endogenous MYC was required
for early reprogramming. Among the three MYC family mem-
bers—MYC (also known as c-MYC), MYCN, and MYCL—we
found that only MYC was expressed in fibroblasts (Figure 2K).
Thus, we knocked down endogenous MYC using short hairpin
RNA (shRNA) in OSK-induced reprogramming (Figure 2L).
However, suppression of endogenous MYC did not alter the
emergence of ESRG (+) cells on day 3 or TRA-1-60 (+) cells on
day 4 (Figure 2M).
(J) MYC does not affect first emergence of TRA-1-60 (+) cells. Percentages of TRA-1-60 (+) cells from MMC-treated (+) or non-treated () HDFs on days 4 and 7
post-transduction of OSK or OSKM are shown. n = 3. See also Figure S2.
(K) Relative expression of MYC family genes c-MYC, MYCN, and MYCL compared to GAPDH expression in iPSCs and fibroblasts (Fib) analyzed by qRT-PCR.
n = 3.
(L) Knockdown of c-MYC in fibroblasts. Shown is the expression of c-MYC in fibroblasts that were introduced with empty vector (Mock) or c-MYC shRNA
analyzed by qRT-PCR. n = 3.
(M) EndogenousMYC does not affect the initiation of reprogramming. Shown are the percentages of ESRG (+) cells (green) on days 3 and 4 and TRA-1-60 (+) cells
on day 4 induced by OSK with or without c-MYC shRNA. n = 3.
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Figure 3. RB Activity Must Be Attenuated for TRA-1-60 (+) Cell Proliferation
(A) Gene set enrichment analysis plot showing enrichment of genes with binding of E2F1 at promoters (±500 bp from the transcription start site) in the set of genes
that show reverse correlation with ESRG expression. x axis shows genes ranked by the Pearson correlation coefficient for ESRG expression. Left, positively
correlated genes; right, negatively correlated genes. See also Figure S3 and Tables S3 and S4.
(B) Phosphorylation statuses of RB during reprogramming. Phosphorylated RBs (upper) and total RBs (lower) during reprogramming fromHDFs to iPSCs induced
by OSKM were detected by western blotting.
(C) Expression of CDK inhibitors in the early stages of reprogramming. Shown are relative expressions of genes encoding CDK inhibitor proteins in ESRG-Clover
fibroblast, ESRG (+), or ESRG () cells on day 3 post-transduction of OSKM analyzed by qRT-PCR. *p < 0.05 versus fibroblasts by unpaired t test (n = 3). See also
Figure S4.
(D) OSK suppresses endogenousMYC expression. Shown is the relative expression of endogenousMYC, total MYC,MYCN, andMYCL compared to expression
of GAPDH in ESRG (+) or ESRG () cells induced by OSK or OSKM on day 3. *p < 0.05 versus fibroblasts by unpaired t test (n = 3).
(legend continued on next page)
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RB Activity Is Crucial for Proliferation Pause in Early
Reprogramming Cells
To address mechanisms of the proliferation pause in early re-
programming cells, we analyzed single-cell RNA-seq data to
determine whether genes that correlated with ESRG expression
associated with a specific functional pathway or pathways
(Table S4). We found that the RB/E2F pathway was highly asso-
ciatedwith genes that inversely correlatedwith ESRGexpression
(Figures 3A andS3). Of 6,717 genes that inversely correlatedwith
ESRG expression and 4,405 genes with promoter regions occu-
pied by E2F1, 2,339 genes overlapped (p < 2.2e16 by Fisher’s
exact test) (Figure 3A). Consistently, western blot analyses
demonstrated that phosphorylated RB, an inactive form of RB,
increased as reprogramming progressed (Figure 3B). We also
found that ESRG (+) cells on day 3 after OSK or OSKM transduc-
tion expressedhigh levels ofCDKN1Aand INK4A (Figures 3Cand
S4A). TP53 mRNA, which encodes the p53 tumor suppressor,
was also induced by OSK or OSKM in ESRG (+) cells (Figures
3C and S4A). Increased p53 at least partly contributed to the in-
crease of CDKN1A mRNA (el-Deiry et al., 1993). In addition, we
found that OSK suppressed the expression of the endogenous
MYC (Figure 3D). All of these changes should contribute to acti-
vation of RB (Mun˜oz-Espı´n and Serrano, 2014), sequestration
of E2F, and decrease of proliferation.
To study the roles of RB1, p16, p21, and p53 in early reprog-
ramming cells, we suppressed their expression using specific
shRNAs. We found that inhibition of these tumor suppressor
genes induced DNA synthesis in ESRG (+) cells on day 3 and
TRA-1-60 (+) cells on day 4, as judged by BrdU incorporation
(Figures 3E, 3F, S4B, and S4C). They also facilitated DNA syn-
thesis of TRA-1-60 (+) cells on day 7 (Figures 3G and S4C). These
data show that the three tumor suppressor gene products, p16,
p21, and p53, cooperatively activate RB and suppress prolifera-
tion. Increased DNA synthesis resulting from RB1 shRNA treat-
ment did not immediately increase the proportion of TRA-1-60
(+) cells on day 4, but it did significantly increase on day 7 after
OSK or OSKM transduction (Figures 3H and S4E). We observed
comparable results with transfection of small interfering RNA
(siRNA) targeting RB1 (Figures 3I and S4F).
Forced expression of the constitutive active mutant of RB
(RB 9I) or p21 strongly suppressed the proliferation of TRA-
1-60 (+) cells on day 7 after OSKM induction (Figures 3E–3G).
As a consequence, activation of the RB pathway significantly
reduced the proportion of TRA-1-60 (+) cells on day 7 after in-
duction of OSKM, but not of OSK (Figures 3G, 3H, S4D, and
S4E). After transduction of RB 9I, along with OSKM, many cells
became positive for senescence-associated b-galactosidase
(b-gal) (Figure 3J). They did not affect the emergence of
ESRG (+) cells on day 3 and TRA-1-60 (+) cells on day 4 (Figures
3E, 3F, S4B, and S4C). These data suggest that RB does not
interfere with the emergence of early reprogramming cells but
does inhibit their proliferation and induce senescence.
MYC Activates LIN41, which Promotes RB Inactivation
To understand how exogenous MYC attenuates RB activity in
early reprogramming cells, we selected 13 pluripotency-associ-
ated genes and transcription factor genes (Figure 4A) from the
list of genes that were commonly upregulated during early re-
programming from five somatic cells (Figure 1A; Table S1).
We examined whether forced expression of these 13 genes
increased the proportion of TRA-1-60 (+) cells. We found that
one of them, LIN41 (also known as TRIM71), significantly
increased TRA-1-60 (+) cells on day 7 after OSKM transduc-
tion (Figure 4A). Although we previously showed that LIN41
enhanced human iPSC generation, its molecular mechanism or
mechanisms remain unclear (Worringer et al., 2014).
Single-cell RNA-seq revealed that endogenous LIN41
expression was detected only in TRA-1-60 (+) cells (Figure 4B).
Compared to the expression pattern of ESRG (Figure 1B), the
expression of LIN41 on day 3 after OSKM transduction was
lower. To confirm this, we examined the expression of LIN41
and ESRG in ESRG-Clover (+) cells on day 3 and TRA-1-60 (+)
cells on day 7 after OSKM transduction (Figure 4C). We found
that LIN41 expression remained low on day 3 but increased
on day 7. Immunocytochemistry detected endogenous LIN41
proteins 7 days after transduction with OSKM, but not OSK (Fig-
ure 4D). However, both OSK and OSKM increased LIN41 mRNA
to comparable levels on day 7 (Figure 4E). We also found that
let-7 family miRNAs, which target LIN41 mRNA to inhibit transla-
tion, were suppressed by MYC (Figure 4F) (Chang et al., 2008).
These data indicate that OSK induces LIN41 mRNA, but without
MYC, LIN41 protein cannot be produced due to let-7.
Knockdown of endogenous LIN41 did not change the
proportion of new TRA-1-60 (+) cells on day 4 but canceled
(E) RB pathway affects proliferation of ESRG (+) cells. Shown are the percentages of ESRG ()/BrdU (+) cells (black), ESRG (+)/BrdU () cells (green), and
ESRG (+)/BrdU (+) cells (red) on day 3 post-transduction of OSKM, along with each indicated factor to ESRG-Clover fibroblasts. *p < 0.05 versus Mock by
unpaired t test (n = 3). See also Figure S4.
(F) RB pathway affects proliferation of new TRA-1-60 (+) cells. Shown are the percentages of TRA-1-60 ()/BrdU (+) cells (black), TRA-1-60 (+)/BrdU () cells
(green), and TRA-1-60 (+)/BrdU (+) cells (red) on day 4 post-transduction of OSKM, along with each indicated factor to HDFs. *p < 0.05 versus Mock by unpaired
t test (n = 3). See also Figure S4.
(G) RB pathway affects proliferation of TRA-1-60 (+) cells. Shown are the percentages of TRA-1-60 ()/BrdU (+) cells (black), TRA-1-60 (+)/BrdU () cells (green),
and TRA-1-60 (+)/BrdU (+) cells (red) on day 7 post-transduction of OSKM, along with each indicated factor to HDFs. *p < 0.05 versus Mock by unpaired t test
(n = 3). See also Figure S4.
(H) Effects of RB on early stage of reprogramming. The graph shows the relative proportion of TRA-1-60 (+) cells 7 days after transduction of OSKM, along with
empty vector (Mock), RB 9I, or RB1 shRNA to HDFs. RB inactivation enhances the proportion of TRA-1-60 (+) cells. *p < 0.05 versus Mock by Dunnett’s test
(n = 3). See also Figure S4.
(I) Inactivation of RB facilitates expansion of early TRA-1-60 (+) cells. Shown are the effects of RB1 knockdown by siRNA transfection on the OSKM-induced
TRA-1-60 (+) cell proportion on day 4 (d4) and day 7 (d7). *p < 0.05 by unpaired t test (n = 3). See also Figure S4.
(J) RB activity is associated with senescence in early phase of reprogramming. Representative images of HDFs 7 days after transduction of OSKM, along with
empty vector (Mock) or RB 9I with staining for senescence-associated b-gal. Bars indicate 200 mm.











































































































































































































































































































































































































































Figure 4. LIN41 Enhances Early Reprogramming Process with RB Inactivation
(A) LIN41 enhances the proportion of TRA-1-60 (+) cells fromHDFs. Shown are relative proportions of TRA-1-60 (+) cells 7 days after transduction of OSKM, along
with each indicated factor to HDFs. *p < 0.05 by Dunnett’s test (n = 3).
(B) LIN41 is activated in TRA-1-60 (+) cells during reprogramming. Shown is the expression of LIN41 during reprogramming from HDFs to iPSCs analyzed by
single-cell RNA-seq. Twenty-four single cells were analyzed for each sample. Red dots indicate median values. Gray hourglass shapes represent the distribution
of RPKM + 1 value.
(legend continued on next page)
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MYC-induced expansion of TRA-1-60 (+) cells on day 7 (Fig-
ure 4G). In contrast, LIN41 knockdown did not affect the propor-
tion of TRA-1-60 (+) cells induced by OSK on days 4 and 7 (Fig-
ure 4G), which was reasonable, because LIN41 protein was not
expressed in these early reprogramming cells after OSK trans-
duction. These data suggest that induction of LIN41 is respon-
sible for the expansion of TRA-1-60 (+) cells by MYC.
We then examined the effect of exogenous LIN41 on early
reprogramming cells. When transduced together with OSK or
OSKM, LIN41 induced proliferation of ESRG (+) cells on day 3
(Figure 4H) and TRA-1-60 (+) cells on day 4 (Figure 4I), as judged
by BrdU incorporation. This is in contrast to MYC, which did not
induce DNA synthesis on days 3 and 4 when co-transduced with
OSK. However, on day 7, both LIN41 and MYC promoted cell
proliferation (Figure 4I) and increased the proportion (Figures
4J) of TRA-1-60 (+) cells. These data suggest that activation of
LIN41 protein expression induced by MYC promotes the expan-
sion of early TRA-1-60 (+) cells.
Next, to confirm whether LIN41 contributes to inactivation of
RB activity, we checked the phosphorylation statuses of RB in
HDFs transduced with OSK and OSKM with or without LIN41.
We found that OSKM, but not OSK, caused the increase of phos-
phorylated RB in HDFs, albeit at a low efficiency (Figures 4K
andS5). Exogenous LIN41with either OSK or OSKMsignificantly
increased phosphorylated RB (Figures 4K and S5). Furthermore,
immunohistochemistry detected many ESRG (+) cells on day 3
that were positive for phosphorylated RB when exogenous
LIN41 was added to OSK or OSKM (Figure 4L). In contrast, we
did not detect phosphorylated RB in ESRG (+) cells without
LIN41. Thus, LIN41 promotes phosphorylation of RB in early
reprogramming cells.
LIN41 Suppresses p21 Protein Expression
To better understand how LIN41 contributes to RB inactivation,
we searched for LIN41’s target RNAs by immunoprecipitation of
endogenous LIN41 from human ESCs. We found that CDKN1A
mRNA encoding p21 was the most highly enriched among
LIN41-bound mRNAs (Figure 5A; Table S5). Other RB-related
genes, including RB1 and INK4A, were not found as LIN41’s
targets. In TRA-1-60 (+) cells on day 7, exogenous LIN41 with
OSK or OSKM significantly lowered the p21 protein level (Fig-
ure 5B). MYC induced LIN41 protein expression and lowered
p21 protein levels, albeit with lower efficiency than exogenous
LIN41 (Figure 5B).
We hypothesized that LIN41, which is an RNA-binding protein,
regulates p21 protein levels rather than transcription in the early
stage of reprogramming. In accordance with this hypothesis,
LIN41 did not affect CDKN1A mRNA expression (Figure 5C).
Immunocytochemistry of cultures on day 7 post-transduction
of various combination of reprogramming factors, such as
OSK; OCT3/4, SOX2, KLF4 and LIN41 (OSKL); OSKM; and
OCT3/4, SOX2, KLF4, MYC and LIN41 (OSKML); showed
a few in which LIN41 and p21 expression overlapped (Fig-
ure 5D). In addition, immunohistochemistry with anti-p21 anti-
body showed that forced expression of LIN41 alone in HDFs
was sufficient to eliminate endogenous p21 proteins, although
the CDKN1A mRNA level was not changed by LIN41 (Figures
5E–5G). These data suggest that CDKN1A mRNA is a direct
target of LIN41 in human cells rather than an ESC-specific
miRNA-dependent mechanism (Chang et al., 2012).
MYC Suppresses p16, Another Mechanism of RB
Inactivation
In addition to LIN41-mediated p21 suppression, we found that
MYC downregulated p16 expression, which was induced by
OSK (Figure 5B). In contrast to the post-transcriptional regula-
tion of p21 encoded by CDKN1A, MYC downregulated the
RNA levels of INK4A in early reprogrammed cells (Figure 5C).
LIN41 affected neither p16 protein nor INK4A mRNA levels
(Figures 5B and 5C). These data suggest MYC suppressed RB
(C) LIN41 is silenced in ESRG (+) cells. Shown is the expression of ESRG and LIN41 in HDFs, ESRG (+) cells, or ESRG () cells on day 3 and TRA-1-60 (+) or TRA-
1-60 () cells on day 7 analyzed by qRT-PCR. *p < 0.05 by unpaired t test (n = 3).
(D) OSKM induces LIN41 protein expression in early stage of reprogramming. Panels show the immunocytochemistry of HDFs transduced with empty vector
(Mock, upper left), OSK (upper right), or OSKM (lower left) with LIN41 (red) and OCT3/4 (green) antibodies. Nuclei were visualized by Hoechst 33342 staining. Bars
indicate 100 mm.
(E) MYC does not affect LIN41 mRNA expression. Shown is the relative expression of LIN41 transcript in TRA-1-60 (+) cells induced by OSK or OSKM on day 7,
compared to Mock. n = 3.
(F) MYC suppresses OSK-induced let-7 expression. Shown is the relative expression of MIRLET7BHG, MIRLET7E, and MIRLET7I pre-miRNAs in ESRG (+) cells
on day 3 and TRA-1-60 (+) cells on day 7 induced by OSK or OSKM, compared to those in fibroblasts (Fib). *p < 0.05 versus fibroblast by unpaired t test (n = 3).
(G) LIN41 is required for efficient reprogramming in the early phase. Shown are the effects of LIN41 knockdown by siRNA transfection on OSK- or OSKM-induced
TRA-1-60 (+) cell proportion on day 4 (d4) and day 7 (d7). *p < 0.05 by unpaired t test (n = 3).
(H) LIN41 affects proliferation of ESRG (+) cells. Shown are the percentages of ESRG ()/BrdU (+) cells (black), ESRG (+)/BrdU () cells (green), and ESRG
(+)/BrdU (+) cells (red) on day 3 post-transduction of OSK or OSKM, along with empty vector (Mock) or LIN41 to ESRG-Clover fibroblasts. *p < 0.05 versus OSK
and yp < 0.05 versus OSKM by unpaired t test (n = 3). OSKM data are identical to Mock in Figure 3E.
(I) LIN41 affects proliferation of TRA-1-60 (+) cells. Shown are the percentages of TRA-1-60 ()/BrdU (+) cells (black), TRA-1-60 (+)/BrdU () cells (green), and
TRA-1-60 (+)/BrdU (+) cells (red) on day 4 and day 7 post-transduction of OSK or OSKM, along with empty vector (Mock) or LIN41 to HDFs. *p < 0.05 versus OSK
and yp < 0.05 versus OSKM by unpaired t test (n = 3). OSKM data are identical to Mock in Figures 3F and 3G.
(J) LIN41 facilitates expansion of early TRA-1-60 (+) cells. Shown are the effects of LIN41 overexpression on OSK- or OSKM-induced TRA-1-60 (+) cell proportion
on day 4 (d4) and day 7 (d7). *p < 0.05 by unpaired t test (n = 3).
(K) LIN41 increases phosphorylation states of RB. Shown are the relative intensities of phosphorylated RB in HDFs, iPSCs, and HDFs expressing OSK, OSKL,
OSKM, or OSKML on day 4 by western blotting. *p < 0.05 versus OSK and yp < 0.05 versus OSKM by t test (n = 3). See also Figure S5.
(L) Status of phosphorylated RB in ESRG (+) cells. Shown are representative images of ESRG (+) cells (green) after 3 days of OSK, OSKL, OSKM, or OSKML
transduction stained with phosphorylated RB (red) antibody. Nuclei (blue) were visualized by Hoechst 33342 staining. The indicated number at the lower-right
corner of each panel is phosphorylated RB (+)/ESRG (+) cells.
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activity via dual inhibition of p16 and p21 by different modes of
actions.
Immortalization Bypasses the Proliferation Pause
We found that a fibroblast line established from an iPSC-derived
teratoma (TdFs) is different from HDFs in that the efficiency
of iPSC generation by OSK alone was significantly higher (Fig-
ure 6A). MYC did not further increase OSK-mediated iPSC
generation from TdFs (Figure 6B). The MYC-independency of
TdFs gave us an unprecedented opportunity to elucidate roles
of MYC in promoting OSK-mediated reprogramming from non-
immortalized cells.
We found that even in TdFs, the proportion of TRA-1-60 (+)
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Figure 5. LIN41 Post-transcriptionally Suppresses p21
(A) LIN41-interacting RNAs. Upper panel shows fold enrichment of precipitated RNAs by LIN41 pull-down compared to those by beads blocked with LIN41
peptides. In addition, RNA expression levels (middle) and rolling median expression levels (lower) are shown. n = 3. See also Table S5.
(B) Western blot showing expression of LIN41, p21, p16, p53, and b-ACTIN proteins in HDFs; in TRA-1-60 (+) cells on day 7 post-transduction of OSK, OSKL,
OSKM, or OSKML; and in iPSCs.
(C) Expression of CDKN1A, INK4A, and TP53 mRNAs in TRA-1-60 (+) cells on day 7 analyzed by qRT-PCR. *p < 0.05 by unpaired t test (n = 3).
(D) Representative immunocytochemistry images of TRA-1-60 (+) cells on day 7 post-transduction of OSK, OSKL, OSKM, or OSKML stained with TRA-1-60
(white), LIN41 (red), and p21 (green) antibodies. Nuclei were visualized using Hoechst 33342 (blue). Bars indicate 25 mm.
(E) LIN41 suppresses p21 protein expression in reprogramming intermediates. Shown are representative images of immunocytochemistry of p21 (green) in HDFs
expressing mCherry (red in left) or LIN41 (red in right). Nuclei were visualized using Hoechst 33342 (blue). Bars indicate 100 mm. White arrowheads indicate the
cells that express both transgene and p21.
(F) LIN41 suppresses the expression of p21 protein. The graph shows the quantitative results of (E). n = 50.
(G) LIN41 does not alter the expression of CDKN1A mRNA. Shown are relative expression of CDKN1A in HDFs expressing mCherry or LIN41. n = 3.
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(Figure 6C). This showed that the initial appearance of reprog-
ramming cells is not responsible for the high reprogramming ef-
ficiency of TdFs. However, 20% of TRA-1-60 (+) cells from
TdFs showed BrdU incorporation on day 4 after OSK or OSKM
(Figure 6D). This resulted in a significant increase of TdF-derived
TRA-1-60 (+) cells to 10% on day 7 (Figure 6C). Inhibiting
endogenous LIN41 or RB1 did not affect the proportion of
TdF-derived TRA-1-60 (+) cells on day 7 (Figure 6C). These
data showed that TdFs do not require MYC to overcome an
RB-mediated proliferation pause in early reprogramming cells.
To clarify why TdFs bypass the proliferation pause, we
analyzed DNA methylation and gene expression in HDFs and
TdFs. CpG sites in the upstream region of the CDKN1A gene in
TdFs and in iPSCs were hyper-methylated compared to those
in HDFs (Figure 6E). In parallel, expression of CDKN1A mRNA
and p21 protein in TdFs was significantly lower than in HDFs
(Figures 6F and 6G). Furthermore, OSK or OSKM transduction
significantly increased CDKN1A expression on day 3 in HDFs,
but not in TdFs (Figure 6H). We also detected lower p16 and
higher phosphorylated RB expression in TdFs than in HDFs
(Figure 6G). However, c-MYC and p53 protein expression in
TdFs was comparable to those in HDFs (Figure 6G). In addition,
TdFs were resistant to premature senescence induced by forced
expression of constitutive active mutant of HRas (HRasV12,
mutated Gly12 to Val) or RB 9I (Figures S6A and S6B). These
data demonstrated that constitutive inactivation of p21, p16,
and RB in TdFs contributes to MYC independency.
We next used TdFs to examine other MYC functions that had
been reported as mechanisms to promote reprogramming,
including changingmetabolisms (Folmes et al., 2013), facilitating
OSK binding to their targets (Soufi et al., 2012), and suppressing









































































































































































































































































































Figure 6. Immortalization Bypasses the Proliferation Pause
(A) Number of iPSC colonies on day 24 derived from 5 3 104 cells of OSKM-transduced HDFs and TdFs. *p < 0.05 by unpaired t test (n = 3).
(B) Effects of exogenous MYC and LIN41 on iPSC generation from HDFs or TdFs. Shown are the number of iPSC colonies from HDFs or TdFs on day 24
post-transduction of OSK, OSKL, OSKM, or OSKML. *p < 0.05 by Dunnett’s test (n = 3).
(C) Effects of LIN41 or RB1 knockdown by siRNA transfection on the OSK- or OSKM-induced TRA-1-60 (+) cell proportion from HDFs or TdFs on days 4 and 7.
*p < 0.05 by Dunnett’s test (n = 3).
(D) Percentage of BrdU incorporation of newly converted TRA-1-60 (+) cells from HDFs or TdFs on day 4 post-transduction of OSK or OSKM. *p < 0.05 by
unpaired t test (n = 3).
(E) DNA methylation status in the upstream region of the CDKN1A gene. Shown are the b value of DNA methylation at each CpG site (blue arrowheads) in the
upstream region of the CDKN1A gene in HDFs (black), TdFs (red), and iPSCs (green) analyzed by Infinium. n = 3.
(F) Relative expression of CDKN1A in HDFs and TdFs analyzed by qRT-PCR. *p < 0.05 versus HDFs by unpaired t test (n = 3).
(G) Western blot showing expression of cell-cycle-related proteins LIN41, p21, p16, p53, MYC, and b-actin proteins in HDFs, TdFs, and iPSCs.
(H) No induction of CDKN1A by OSKM in TdFs. Shown is the relative expression of CDKN1A mRNA in HDFs (black) or TdFs (red) on day 3 post-transduction of
empty vector (Mock), OSK, or OSKM. *p < 0.05 by Dunnett’s test (n = 3).
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We cultured HDFs, TdFs, and iPSCs in culture media containing
2-deoxy-D-glucose (2-DG), a potent blocker of glycolytic meta-
bolism (Woodward and Hudson, 1954). In this condition, iPSCs
did not survive, because they largely depend on glycolytic
metabolism (Figure S6C). In contrast, both HDFs and TdFs
proliferated normally. In addition, we examined expression levels
of oxidative phosphorylation markers (e.g., ACO1, IDH2, MDH1,
and SDHD) and glycolysis markers (e.g., ENO3, PYGM,
SLC16A1, and SLC2A4) (Varum et al., 2011) by qRT-PCR. We
found that TdFs and HDFs share similar expression patterns,
indicative of oxidative metabolism (Figure S6D). Thus, it is un-
likely that metabolic effects of MYC play a major role in promot-
ing iPSC generation.
We next examinedwhether OSKbinding sites aremore acces-
sible in TdFs than in HDFs. To this end, we analyzed DNAmethyl-
ation signatures ofCpG islands ofOSKbinding sites (FigureS6E).
We found no evidence that these sites were open, as character-
ized by lower DNA methylation. TdFs showed slightly but signif-
icantly higher DNA methylation for all three transcription factors:
OSK. In addition, the expression levels of OSK-binding genes
were comparable in TdFs and HDFs (Figure S6F). Thus, increase
in OSK binding is not responsible for the high reprogramming
efficiency of TdFs.
Finally, we examined the expression levels of fibroblast-spe-
cific genes. We selected 2,449 genes whose expression levels
were at least 5-fold higher in HDFs than in iPSCs. RNA-seq ana-
lyses showed that the expression levels of these genes were
significantly lower in TdFs than in HDFs but still higher than in
iPSCs (Figure S6G). This result suggest that the suppression of
fibroblast-specific genes may also contribute to the high reprog-
ramming efficiency of TdFs.
DISCUSSION
MYC affects several important biological processes through
DNA binding and subsequent transcriptional activation or inhibi-
tion of a diverse set of target genes. To define MYC’s role in re-
programming, previous reports compared OSK to OSKM re-
programming and found several MYC-dependent correlations.
These include enhancement or alteration of OSK binding,
promotion of ESC-like metabolic changes, and enhancement
of proliferation (Chappell and Dalton, 2013; Soufi et al., 2012;
Sridharan et al., 2009). Each of these observed changes may
or may not play a major role in the outcome of reprogramming
(enhanced colony formation), and we are cognizant of the gap
between correlation and causation in this complicated system.
To specifically address the significance of a particular function
of a multifunctional protein, we need to isolate that particular
function and determine its importance. Mutating MYC to isolate
a specific biological process (chromatin accessibility versus
metabolism versus proliferation) is not feasible: varied biological
pathways depend on this transcription factor. In this work, we
identified two methods for replacing one particular aspect—
enhancement of proliferation—of MYC. This enabled us to weigh
MYC’s contribution to proliferation in reprogramming. Both of
these methods are discussed in detail here.
In addition to the strategies for replacing MYC, identification
of ESRG as an early maker of reprogramming proved useful,
because it allowed us to precisely define cellular and molecular
events during the first few days after OSK or OSKM induction.
Our data demonstrate that OSK elicits two important molecular
events in human cells: the initiation of the reprogramming pro-
cess and the RB-mediated proliferation pause or blockade.
MYC does not affect the first event, but it promotes iPSC gener-
ation by escaping the proliferation pause.
The first molecular event that OSK elicits is initiation of the re-
programming process, including activating early markers such
as ESRG and TRA-1-60. We and others report that activation
of endogenous retroviruses is crucial for iPSC generation
in human cells. ESRG is a lncRNA driven by long terminal repeat
(LTR) 7 of a HERV-H group endogenous retrovirus (Li et al., 2013;
Lu et al., 2014; Ohnuki et al., 2014; Wang et al., 2014). We found
that the LTR7 of ESRG contains the binding site of KLF4,
suggesting that OSK directly activates its expression (Ohnuki
et al., 2014). To our surprise, MYC did not promote this initial
process of reprogramming. This is in contrast to a previous
report that MYC enhanced the binding of OSK to its targets.
Furthermore, we found that even endogenous MYC seemed
dispensable for the appearance of ESRG (+) cells. Thus, MYC
does not play a crucial role in this early event during human
iPSC generation.
The other molecular event that OSK elicits is the proliferation
pause in early reprograming cells. Few BrdU (+) cells were de-
tected in ESRG (+) cells on day 3 and TRA-1-60 (+) cells on
day 4 after induction of OSK. We found that the OSK-mediated
proliferation pause was attributable to RB activation. We also
found that OSK induced expression of p16 and p53. OSK also
induced a transient increase in p21 mRNA levels on day 3. Sup-
pression of these genes by shRNAs induced proliferation. Thus,
cooperation of these multiple tumor suppressor gene products
is responsible for RB activation and the proliferation pause in
early reprogramming cells. Previously, evidence of an onco-
gene-induced, senescence-like process was detected via tran-
scriptional changes and described as reprogramming-induced
senescence (Banito et al., 2009; Utikal et al., 2009). In this paper,
we refer to the period from day 3 to day 7 as a proliferation pause
or blockade, but we have no objection to alternatively calling the
OSK-initiated, p21/p16-driven cessation of proliferation a re-
programming-induced senescence. We think the two processes
are likely the same. With regards to this process, this work dem-
onstrates the utility of ESRG to define the precise timing and
demonstrates the mechanisms by which reprogramming cells
are able to overcome this blockade.
MYC provided an escape from the proliferation pause elicited
by OSK in early reprogramming cells. An important mechanism
is the let-7/LIN41/p21 axis. OSK increased transcripts of let-7
family members, but addition of MYC suppressed this increase.
We found that LIN41 mRNA expression was induced by OSK in
early reprogramming cells. However, the LIN41 protein level re-
mained low due to the increased expression of let-7 that inhibits
translation of LIN41 mRNA (Lin et al., 2007; Slack et al., 2000).
MYC, by suppressing let-7 expression, increases LIN41 protein.
We also found that CDKN1A mRNA encoding p21 is the most
enriched mRNA binding target in LIN41 pull-down from human
ESCs (Figure 5A). Furthermore, LIN41 expression in fibroblasts
dramatically represses p21 translation (Figure 5E). Thus, MYC
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decreased p21 protein expression, leading to inactivation of RB
and initiation of proliferation.
Though less dramatic than the effects on the let-7/LIN41/p21
axis, we additionally found that MYC decreased mRNA and
protein levels of p16. When MYC alone is overexpressed, it in-
duces p16 expression (Guney et al., 2006), but when it is co-ex-
pressed with RAS, MYC suppresses RAS-induced senescence
(Hydbring et al., 2010). We suspect that a similar mechanism
operates during reprogramming. In contrast to p16, MYC
increased mRNA expression of p53, which should have an inhib-
itory influence on reprogramming (Figure 5C). We suppose that
the suppression of p21 and p16 is sufficient to overcome nega-
tive effects of increased p53.
Because a proliferation pause was commonly observed in
early reprogramming cells derived from five types of somatic
cells, it might be a required step for reprogramming. However,
TdFs reprogram without going through a proliferation pause.
Furthermore, addition of exogenous LIN41 with OSK allows
even somatic cells to avoid the onset of the proliferation pause.
Therefore, a proliferation pause is not required in reprogram-
ming; instead, it is a barrier to reprogramming that is com-
mon to normal somatic cells (five of five lines) when induced
with OSK.
TdFs gave us a unique opportunity to delineate the roles of
MYC in promoting reprogramming. TdFs were highly efficient
in iPSC generation, and MYC did not enhance reprogramming.
This suggests that the main role or roles of MYC are already
achieved in TdFs. We found that an RB-mediated proliferation
pause does not occur in TdFs even without exogenous MYC.
OSK and OSKM reprogramming efficiencies were equal (Fig-
ure 6B). In contrast, we did not observe metabolic changes in
favor of reprogramming in TdFs (Figure S6C). Our data also sug-
gested that the binding of OSK to their targest was comparable
between TdFs and HDFs (Figures S6E and S6F). We did observe
a significant downregulation of fibroblast-specific genes in TdFs
compared to HDFs, suggesting that this intermediate level of
expression may contribute to high reprogramming efficiency of
TdFs (Figure S6G). However, given that TdFs have an intermedi-
ate level of HDF markers, further downregulation of many fibro-
blast-related genes and upregulation of many ESC-related
genes are necessary to form iPSCs. If the previously proposed
chromatin accessibility role ofMYC significantly affected reprog-
ramming efficiency, we would expect that TdFs would show a
partial improvement upon addition ofMYC. In addition, wewould
expect that the emergence of early reprogramming cells should
be increased regardless of whether the downregulation of the
fibroblast genetic program offered an easier route to reprogram-
ming. Neither of these predictions (depending on a significant
role for chromatin remodeling by MYC in reprogramming) is
true in TdFs. Because proliferation pause-resistant TdFs do
not benefit from MYC, we conclude that the main contribution
of MYC in proliferation pause-responsive somatic cells is to
overcome proliferation pause rather than to improve reprogram-
ming through other means, such as chromatin accessibility.
We previously showed that LIN41, a cytoplasmic protein
and a let-7 miRNA translationally repressed target, dramatically
enhanced iPSC generation (Worringer et al., 2014). We identified
EGR1, a transcription factor involved in differentiation, as a
target of LIN41. We showed that EGR1 protein was upregulated
by LIN41 knockdown and LIN41 overexpression suppressed
iPSC generation. Based on these data, we hypothesized that
positive action of LIN41 in reprogramming is attributable to sup-
pression of EGR1. However, our current results clearly show that
p21 is the most crucial target of LIN41 in promoting iPSC gener-
ation. LIN41 enhances the reprogramming of OSK to the same
extent as MYC (Figure 6B, see the right side of the HDF section).
This is not coincidental, because LIN41 andMYC provide similar
outcomes with regard to proliferation pause. OSKL reprog-
rammed cells subverted the proliferation pause by early and tight
translational suppression of p21. OSKM entered the proliferation
pause but eventually escaped after downregulation of let-7
miRNA, followed by derepression of endogenous LIN41 protein
and subsequently p21 translational silencing. Again, LIN41 likely
replaced only one specific biological function out of the various
proposed mechanisms of MYC, but it achieved all of MYC’s
reprogramming enhancement. We therefore conclude that the
significant contribution of MYC is that shared with LIN41—the
ability to overcome proliferation pause.
We believe that the metabolic effects described as contingent
upon MYC could be viewed as secondary to escape from the
proliferation pause. In other words, when OSK is compared to
OSKM, one is comparing blocked cells to cells that have
escaped proliferation pause, continue to reprogram, and thus
are continuing to gain ESC-like attributes (e.g., ESC-like meta-
bolism). Regardless of whether a metabolic contribution is pro-
vided by MYC through transcriptional activation of metabolic
genes or as a consequence of escape from the proliferation
blockade, we find that an equivalent outcome is obtained by
two methods that likely replace only MYC’s effect on prolifera-
tion. Therefore, we favor a model emphasizing MYC’s contribu-
tion as facilitating escape from a proliferation pause.
In conclusion, our data showed that the main function of MYC
during human iPSC generation is to override an RB-mediated
proliferation pause in early reprogramming cells. MYC achieves
this by suppressing let-7 miRNA and derepressing endogenous
LIN41 transcript. This leads to LIN41 protein-dependent transla-
tional repression of p21. Exogenous LIN41 fulfills the role of
endogenous LIN41 and therefore MYC. In TdFs, the proliferation
pause does not operate during reprogramming, resulting in
MYC-independent high efficiency of iPSC generation. However,
the emergence of early reprogramming cells is inefficient even
with MYC or in TdFs. Therefore, the RB pathway is responsible
for the proliferation pause, but not the low efficiency of the
appearance of early reprogramming cells. Understanding the
cause of the low conversion efficiency to the state demarcated
by ESRG positivity—an early prerequisite for, but not a guar-
antee of, inevitable reprogramming—remains an important
future task.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in the
Supplemental Experimental Procedures.
Quantification and Statistical Analysis
Data are presented as mean ± SD. Sample number (n) indicates the number of
biological replicates in each experiment. The number of experimental repeats
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is indicated in figure legends. To determine statistical significance, we used
Dunnett’s test for one-to-many comparisons and unpaired t test for compari-
sons between two groups using Excel 2013 (Microsoft) and Kaleida graph soft-
ware (HULINKS) unless otherwise noted. Statistical significance in the main
figures was set at p < 0.05, as indicated by an asterisk.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the gene expression microarray, Infinium, and
deep sequencing results reported in this paper are GEO: GSE89455 and




Supplemental Information includes Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at https://
doi.org/10.1016/j.celrep.2018.03.057.
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